Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeted chimeric antigen receptor insertion into regulatory T cells using non-viral approaches

EF 2022-23

Résumé
Type 1 diabetes (T1D) occurs when the immune system destroys insulin-producing cells known as beta cells. Beta cells are found in clusters of the pancreas called islets so transplanting islets can restore insulin production. To protect transplants, people take non-specific drugs that minimize negative immune responses, but these drugs leave patients with increased risks of infection and cancer. An alternative to these drugs is a type of white blood cell, regulatory T cells (Tregs). Tregs limit harmful immune responses, such as negative responses against transplants, but in a more specific way. Clinical trials suggest that Treg injection is safe, but currently only a small number of Tregs are disease relevant so benefits for T1D have yet to be observed. Treg function can be improved by genetically editing them to make synthetic proteins that better target their response. The current approaches to edit Tregs have drawbacks such as high cost and the chance of incorrect genetic changes. My project aims to develop better ways to genetically edit Tregs to increase accuracy and restrict expression of the synthetic proteins to the most suppressive Treg type. First, I will apply a new way to introduce DNA into Tregs without virus that has been described in T cells. Then I will design ways to target new genetic material to a precise location in the genome so expression is restricted to Tregs which express a protein known as Helios. Helios-expressing Tregs are the best kind of suppressive cell so this approach should focus synthetic protein expression to this cell type. Overall, my work will improve safety and function of Treg cell therapy for islet transplantation, providing better T1D treatment options that can be applied to other cases of autoimmunity and transplantation.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
485918
Name
Mangat Jaspreet
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted chimeric antigen receptor insertion into regulatory T cells using non-viral approaches
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chimeric Antigen Receptors; Genomic Engineering; Immunotherapy; Islet Transplantation; Regulatory T Cells
Abstract
Type 1 diabetes (T1D) occurs when the immune system destroys insulin-producing cells known as beta cells. Beta cells are found in clusters of the pancreas called islets so transplanting islets can restore insulin production. To protect transplants, people take non-specific drugs that minimize negative immune responses, but these drugs leave patients with increased risks of infection and cancer. An alternative to these drugs is a type of white blood cell, regulatory T cells (Tregs). Tregs limit harmful immune responses, such as negative responses against transplants, but in a more specific way. Clinical trials suggest that Treg injection is safe, but currently only a small number of Tregs are disease relevant so benefits for T1D have yet to be observed. Treg function can be improved by genetically editing them to make synthetic proteins that better target their response. The current approaches to edit Tregs have drawbacks such as high cost and the chance of incorrect genetic changes. My project aims to develop better ways to genetically edit Tregs to increase accuracy and restrict expression of the synthetic proteins to the most suppressive Treg type. First, I will apply a new way to introduce DNA into Tregs without virus that has been described in T cells. Then I will design ways to target new genetic material to a precise location in the genome so expression is restricted to Tregs which express a protein known as Helios. Helios-expressing Tregs are the best kind of suppressive cell so this approach should focus synthetic protein expression to this cell type. Overall, my work will improve safety and function of Treg cell therapy for islet transplantation, providing better T1D treatment options that can be applied to other cases of autoimmunity and transplantation.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mangat, Jaspreet
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~